Literature DB >> 24760108

Fc glycan-modulated immunoglobulin G effector functions.

Isaak Quast1, Jan D Lünemann.   

Abstract

Immunoglobulin G (IgG) molecules are glycoproteins and residues in the sugar moiety attached to the IgG constant fragment (Fc) are essential for IgG functionality such as binding to cellular Fc receptors and complement activation. The core of this sugar moiety consists of a bi-antennary heptameric structure of mannose and N-acetylglucosamine (GlcNAc), further decorated with terminal and branching residues including galactose, sialic acid, fucose, and GlcNAc. Presence or absence of distinct residues such as fucose and sialic acid can dramatically alter pro- and anti-inflammatory IgG activities which could be harnessed for immunotherapeutic purposes. Here we review recent advances in understanding the role of the IgG-Fc glycan during immune responses and for immunotherapy with a focus on sialic acid and intravenous immunoglobulin (IVIG) treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24760108     DOI: 10.1007/s10875-014-0018-3

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  58 in total

1.  Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.

Authors:  Ryan J Hansen; Joseph P Balthasar
Journal:  Thromb Haemost       Date:  2002-12       Impact factor: 5.249

2.  IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1.

Authors:  Inessa Schwab; Markus Biburger; Gerhard Krönke; Georg Schett; Falk Nimmerjahn
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

3.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

4.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

5.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

Review 6.  The impact of glycosylation on the biological function and structure of human immunoglobulins.

Authors:  James N Arnold; Mark R Wormald; Robert B Sim; Pauline M Rudd; Raymond A Dwek
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

7.  Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum.

Authors:  E Yamada; Y Tsukamoto; R Sasaki; K Yagyu; N Takahashi
Journal:  Glycoconj J       Date:  1997-04       Impact factor: 2.916

Review 8.  Emerging methods for the production of homogeneous human glycoproteins.

Authors:  Jamie R Rich; Stephen G Withers
Journal:  Nat Chem Biol       Date:  2009-04       Impact factor: 15.040

9.  Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.

Authors:  Rinpei Niwa; Emi Shoji-Hosaka; Mikiko Sakurada; Toyohide Shinkawa; Kazuhisa Uchida; Kazuyasu Nakamura; Kouji Matsushima; Ryuzo Ueda; Nobuo Hanai; Kenya Shitara
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy.

Authors:  Rick Kapur; Iwan Kustiawan; Anne Vestrheim; Carolien A M Koeleman; Remco Visser; Helga K Einarsdottir; Leendert Porcelijn; Dave Jackson; Belinda Kumpel; André M Deelder; Dennis Blank; Björn Skogen; Mette Kjaer Killie; Terje E Michaelsen; Masja de Haas; Theo Rispens; C Ellen van der Schoot; Manfred Wuhrer; Gestur Vidarsson
Journal:  Blood       Date:  2013-11-15       Impact factor: 22.113

View more
  22 in total

Review 1.  Regulation of antibody effector functions through IgG Fc N-glycosylation.

Authors:  Isaak Quast; Benjamin Peschke; Jan D Lünemann
Journal:  Cell Mol Life Sci       Date:  2016-09-17       Impact factor: 9.261

Review 2.  Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-08-16       Impact factor: 4.481

3.  CD68/macrosialin: not just a histochemical marker.

Authors:  Dimitry A Chistiakov; Murry C Killingsworth; Veronika A Myasoedova; Alexander N Orekhov; Yuri V Bobryshev
Journal:  Lab Invest       Date:  2016-11-21       Impact factor: 5.662

Review 4.  New therapies for hemophilia.

Authors:  Steven W Pipe
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Clinical Efficacy of Immunoglobulin Combined with Glucocorticoids in the Treatment of Oculomotor Myasthenia Gravis in Children and the Effect on Serum Immunity.

Authors:  Lijun Fan; Yahui Yang; Fan Zhang; Fei Huang
Journal:  Comput Math Methods Med       Date:  2022-07-08       Impact factor: 2.809

6.  Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab.

Authors:  Giovanna Scapin; Xiaoyu Yang; Winifred W Prosise; Mark McCoy; Paul Reichert; Jennifer M Johnston; Ramesh S Kashi; Corey Strickland
Journal:  Nat Struct Mol Biol       Date:  2015-11-23       Impact factor: 15.369

Review 7.  Future perspectives in target-specific immunotherapies of myasthenia gravis.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

Review 8.  Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions.

Authors:  Connie M Arthur; Satheesh Chonat; Ross Fasano; Marianne E M Yee; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Transfus Med Rev       Date:  2019-10-18

9.  IgG Glycome in Colorectal Cancer.

Authors:  Frano Vučković; Evropi Theodoratou; Kujtim Thaçi; Maria Timofeeva; Aleksandar Vojta; Jerko Štambuk; Maja Pučić-Baković; Pauline M Rudd; Lovorka Đerek; Dražen Servis; Annika Wennerström; Susan M Farrington; Markus Perola; Yurii Aulchenko; Malcolm G Dunlop; Harry Campbell; Gordan Lauc
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531

10.  Variability of serum IgG sialylation and galactosylation degree in women with advanced endometriosis.

Authors:  Katarzyna Sołkiewicz; Hubert Krotkiewski; Marcin Jędryka; Ewa M Kratz
Journal:  Sci Rep       Date:  2021-03-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.